Ivabradine in Management of Heart Failure: a Critical Appraisal

Gabriela Orasanu, Sadeer G. Al-Kindi, Guilherme H. Oliveira

Research output: Contribution to journalReview articlepeer-review


Elevated resting heart rate has been linked to poor outcomes in patients with chronic systolic heart failure. Blockade of funny current channel with ivabradine reduces heart rate without inotropic effects. Ivabradine was recently approved by US Food and Drug Administration for patients with stable, symptomatic chronic heart failure (HF) with left ventricular ejection fraction (LVEF) ≤35 %, who are in sinus rhythm with resting heart rate (HR) ≥ 70 bpm and either are on maximally tolerated doses of beta-blockers, or have a contraindication to beta-blockers. This article will review and evaluate the data supporting the use of ivabradine in patients with HF and explore its mechanisms and physiologic effects.

Original languageEnglish (US)
Pages (from-to)60-69
Number of pages10
JournalCurrent heart failure reports
Issue number1
StatePublished - Feb 1 2016


  • Funny channel
  • Heart failure
  • Heart rate
  • Hospitalization
  • Inhibitor
  • Ivabradine

ASJC Scopus subject areas

  • Emergency Medicine
  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)


Dive into the research topics of 'Ivabradine in Management of Heart Failure: a Critical Appraisal'. Together they form a unique fingerprint.

Cite this